ASH 2023 Myeloid Recap With Anand Patel, MD

In this episode of “Blood Cancer Talks,” Anand Patel, MD, Assistant Professor of Medicine at the University of Chicago, joins hosts Raj Chakraborty, MD; Ashwin Kishtagari, MD; and Edward Cliff, MD, to discuss the top abstracts in the myeloid space presented at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.

Dr. Patel and the hosts first discuss the TRANSFORM-1 study, a randomized, multicenter, phase III study of navitoclax in combination with ruxolitinib versus ruxolitinib plus placebo in patients with untreated myelofibrosis (MF).

They also discuss the following studies:

• MANIFEST-2, a phase III study of pelabresib in combination with ruxolitinib for janus kinase inhibitor treatment-naïve patients with MF
• AUGMENT-101, which studied revumenib monotherapy in patients with relapsed or refractory KMT2Ar acute lymphoblastic leukemia and acute myeloid leukemia (AML)
• The FILO study, which looked at treatment-free remission and overall survival in patients with AML who stopped venetoclax and/or azacitidine

This podcast originally appeared on Blood Cancer Talks.